Caribou Biosciences Inc. Common Stock (CRBU)

About CRBU

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

97

Website

www.cariboubio.com/

Fundamentals

1-day range

$1.6$1.66

Market cap

$148.77M

P/E (trailing)

—

P/E (forward)

-1.28

EPS (trailing)

$-1.42

Dividend yield

—

Beta

2.37

Avg. volume

1.78M

Forecasts

7 analyst ratings

Caribou Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• ENGN

  enGene Therapeutics Inc. Common Stock

  $1.83

  ▼ 4.19%
  Market cap $118.57MP/E —
  $1.4$12.25
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
  benzinga · 8/14/2026
• B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
  Benzinga · 8/14/2026
• Adicet Bio: A Cheap Gamma Delta T-Cell Play
  SeekingAlpha · 8/14/2026
• Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
  Benzinga · 8/13/2026

Institutional Ownership

March 31, 2026

Total shares held

37.71M

Total value held

$67.17M

Institutional holders

131